Biomarkers to Enhance Early Schizophrenia Treatment

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

CT.gov Identifier
NCT06969755
EudraCT Identifier
N/A
CTIS:
N/A
Sponsor
National Institutes of Health/National Institute of Mental Health
Collaborator
Northwell Health
Study Contact Information
N/A
Recruiting
Contact Us

Study Details

Diseases
Monogenic obesity
Study Drug
Risperidone
See More
Aripiprazole
Clozapine
Genes
MC4R
Study Dates
Sep 2025 - Jul 2030
Sex
Female & Male
Age
18 - 35 Years
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • 1. Aged 18 to 35.
  • 2. DSM5 diagnosis (as determined by the SCID5) of schizophrenia, schizoaffective disorder, schizophreniform disorder.
  • 3. Current positive symptoms rated ≥4 (moderate) on one or more of the following BPRS positive subscale items: unusual thought content, conceptual disorganization, hallucinatory behavior, suspiciousness.
  • 4. Preserved striatal connectivity, as determined by screening MRI scan
  • 5. Absence of the MC4R high-risk genotype, as determined by genetic testing
  • 6. Absence of the HLA-DQB1 high-risk genotype, as determined by genetic testing
  • 7. In an early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 4 weeks or less (with exceptions of very low doses for other off-label indications, e.g. sleep)
  • 8. Ability to provide informed consent
Exclusion Criteria:
  • 1. The patient reports or medical records state a serious neurological or endocrine disorder at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
  • 2. An abnormal EKG at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
  • 3. Any medical condition which requires treatment with a medication with psychotropic effects.
  • 4. Significant risk of suicidal or homicidal behavior (i.e. 'severe' risk on the Columbia Suicide Scale, a 'hostility' score of 7 on the BPRS, or an answer of 'yes' on questions 4,5 or 6 on the CDSS).
  • 5. Cognitive limitations, or any other factor that would preclude potential participants providing informed consent
  • 6. Contraindications to MRI (e.g. pacemaker).
  • 7. Meeting SCID-5 substance use disorder moderate or severe for any substance, other than nicotine within 3 months of screening visit. Meeting SCID5 substance use disorder mild for any substance other than cannabis, alcohol, or nicotine for less than 3 months prior to screening visit, or a positive urine baseline drug screen with a substance other than nicotine, alcohol, or cannabis
  • 8. Suspected DSM5 intellectual disability based upon clinical interview and psychosocial history, as well as screening with the Weschler Test for Adult Reading (IQ score <71)
  • 9. Prior psychosurgery
  • 10. Pregnancy (self-report)
  • 11. Seizure disorder (self-report)
  • \-

Protocol Summary

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.